CD4 and cancer: A recent consensus by the European Organization for Research and Treatment of Cancer (EORTC) has suggested defining blood involvement based on phenotypical, rather than morphological, criteria in the presence of more than 1000/mm3 CD4+ CD26− or CD4+ CD7− cells [4].